Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Viewray Inc (VRAY)

Viewray Inc (VRAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets PR Newswire - Fri Jul 21, 2023

/PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department...

VRAY : 0.0250 (-39.90%)
ViewRay® Files Voluntary Chapter 11 Petitions PR Newswire - Mon Jul 17, 2023

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions...

VRAY : 0.0250 (-39.90%)
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System PR Newswire - Tue Jun 13, 2023

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy...

VRAY : 0.0250 (-39.90%)
ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting PR Newswire - Fri May 12, 2023

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual...

VRAY : 0.0250 (-39.90%)
ViewRay: Q1 Earnings Snapshot AP - Wed May 10, 2023

ViewRay: Q1 Earnings Snapshot

VRAY : 0.0250 (-39.90%)
ViewRay Announces First Quarter 2023 Results PR Newswire - Wed May 10, 2023

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023...

VRAY : 0.0250 (-39.90%)
ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023 PR Newswire - Tue May 9, 2023

/PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a...

VRAY : 0.0250 (-39.90%)
ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value PR Newswire - Thu Apr 13, 2023

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended...

VRAY : 0.0250 (-39.90%)
ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023 PR Newswire - Wed Apr 12, 2023

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for...

VRAY : 0.0250 (-39.90%)
Military University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer Patients PR Newswire - Tue Mar 7, 2023

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the Czech Ministry of Health has approved the purchase of ViewRay's MRIdian system to bring...

VRAY : 0.0250 (-39.90%)

Barchart Exclusives

Anterix Stock Has Nearly Quadrupled Over the Past Year and Could Still Go Higher Barchart - Tue Aug 4, 11:15PM CDT
Anterix (ATEX) has surged 380% over the past year, recently hitting an all-time high of $113. ATEX maintains strong technical momentum with a 100% “Buy” rating from Barchart. Revenue is forecast to grow 220.2% this year and 33.7% next year, supporting continued bullish sentiment. Valuation concerns persist, with Seeking Alpha... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.